IFNA1 and chronic obstructive pulmonary disease: Thus, FP administration in both in vitro and in vivo COPD models was associated with suppressed IFN responses, confirming that these adverse effects still occur in steroid-resistant disease models, and the increased virus load and mucus production observed in vivo could impact adversely on exacerbation severity.